BFA
NVO

Bill Few Associates’s Novo Nordisk NVO Stock Holding History

Bill Few Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,017
Closed -$223K – 208
2025
Q3 		$223K Buy
4,017
+817
+26% +$47.8K 0.06% 182
2025
Q2 		$221K Sell
3,200
-150
-4% -$10.2K 0.06% 181
2025
Q1 		$233K Buy
3,350
+100
+3% +$8.26K 0.08% 156
2024
Q4 		$280K Sell
3,250
-100
-3% -$10.8K 0.1% 142
2024
Q3 		$399K Hold
3,350
– – 0.14% 116
2024
Q2 		$478K Buy
3,350
+400
+14% +$53K 0.18% 99
2024
Q1 		$379K Buy
2,950
+550
+23% +$65.5K 0.15% 108
2023
Q4 		$248K Hold
2,400
– – 0.11% 130
2023
Q3 		$218K Buy
+2,400
New +$211K 0.11% 125

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bill Few Associates's NVO Position: Q4 2025 in Review

Bill Few Associates sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 4,017 shares — an estimated $223K sold.

Bill Few Associates first reported a position in NVO in Q3 2023 and held it in 9 quarters. The position peaked at $478K in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Bill Few Associates reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Bill Few Associates sold 4,017 Novo Nordisk shares in Q4 2025, an estimated $223K.
  • Bill Few Associates first reported a position in Novo Nordisk in Q3 2023 and held it in 9 quarters.
  • Bill Few Associates's Novo Nordisk position peaked at $478K in Q2 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Bill Few Associates's 13F filing for Q4 2025, filed 12 Jan 2026.